AU2004258821A1 - Antibacterial methods and compositions - Google Patents

Antibacterial methods and compositions Download PDF

Info

Publication number
AU2004258821A1
AU2004258821A1 AU2004258821A AU2004258821A AU2004258821A1 AU 2004258821 A1 AU2004258821 A1 AU 2004258821A1 AU 2004258821 A AU2004258821 A AU 2004258821A AU 2004258821 A AU2004258821 A AU 2004258821A AU 2004258821 A1 AU2004258821 A1 AU 2004258821A1
Authority
AU
Australia
Prior art keywords
aureus
mupirocin
composition
mrsi
trna synthetase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004258821A
Other languages
English (en)
Inventor
Ian A. Critchley
Joseph Guiles
Nebojsa Janjic
Theodore M. Tarasow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiovascular Systems Inc
Original Assignee
Replidyne Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replidyne Inc filed Critical Replidyne Inc
Publication of AU2004258821A1 publication Critical patent/AU2004258821A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2004258821A 2003-05-01 2004-05-03 Antibacterial methods and compositions Abandoned AU2004258821A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46737703P 2003-05-01 2003-05-01
US60/467,377 2003-05-01
US48648203P 2003-07-10 2003-07-10
US60/486,482 2003-07-10
PCT/US2004/013614 WO2005009336A2 (en) 2003-05-01 2004-05-03 Antibacterial methods and compositions

Publications (1)

Publication Number Publication Date
AU2004258821A1 true AU2004258821A1 (en) 2005-02-03

Family

ID=34107519

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004258821A Abandoned AU2004258821A1 (en) 2003-05-01 2004-05-03 Antibacterial methods and compositions

Country Status (6)

Country Link
US (1) US20040224981A1 (https=)
EP (1) EP1619947A4 (https=)
JP (1) JP2007502861A (https=)
AU (1) AU2004258821A1 (https=)
CA (1) CA2523651A1 (https=)
WO (1) WO2005009336A2 (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078119A2 (en) * 2003-03-03 2004-09-16 Replidyne Inc. Substituted thiophenes with antibacterial activity
CA2602522C (en) 2005-03-23 2014-09-09 Oculus Innovative Sciences, Inc. Method of treating skin ulcers using oxidative reductive potential water solution
WO2006117762A2 (en) 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited Antimicrobial agents
EP1993571B1 (en) 2006-01-20 2018-07-25 Sonoma Pharmaceuticals, Inc. Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution
WO2008039639A2 (en) * 2006-09-26 2008-04-03 Crestone, Inc. Substituted thienopyridone compounds with antibacterial activity
EP2091536B1 (en) * 2006-09-26 2013-07-31 Crestone, Inc. Enantiomeric compounds with antibacterial activity
EP2403864B1 (en) 2009-02-27 2015-08-12 Atyr Pharma, Inc. Polypeptide structural motifs associated with cell signaling activity
WO2010148004A1 (en) 2009-06-15 2010-12-23 Oculus Innovative Sciences, Inc. Solution containing hypochlorous acid and methods of using same
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (en) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
AU2011248521B2 (en) 2010-04-27 2017-03-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of threonyl tRNA synthetases
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
EP2566516B1 (en) 2010-05-03 2019-07-03 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-trna synthetases
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
ES2668207T3 (es) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103096909A (zh) 2010-05-04 2013-05-08 Atyr医药公司 与谷氨酰-脯氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
US9034598B2 (en) 2010-05-17 2015-05-19 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
KR20180059575A (ko) 2010-07-12 2018-06-04 에이티와이알 파마, 인코포레이티드 아스파르틸­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
US8999321B2 (en) 2010-07-12 2015-04-07 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
KR20130102534A (ko) 2010-07-12 2013-09-17 에이티와이알 파마, 인코포레이티드 히스티딜­trna 합성효소의 단백질 단편에 관련된 치료적, 진단적, 및 항체 조성물의 혁신적 발견
WO2012014109A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Heterocyclic sulfonamides as inhibitors of transfer rna synthetase for use as antibacterial agents
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CN103118696B (zh) 2010-10-06 2020-02-14 Atyr 医药公司 与色氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物
US20130245060A1 (en) * 2010-10-08 2013-09-19 Helperby Therapeutics Limited Novel composition
WO2012054738A1 (en) * 2010-10-22 2012-04-26 Brown University Combination of an aminoacyl - trna synthetase inhibitor with a further antibacterial agent for attenuating multiple drug resistance
US9714419B2 (en) 2011-08-09 2017-07-25 Atyr Pharma, Inc. PEGylated tyrosyl-tRNA synthetase polypeptides
WO2013086228A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Pegylated aspartyl-trna synthetase polypeptides
WO2013086216A1 (en) 2011-12-06 2013-06-13 Atyr Pharma, Inc. Improved aspartyl-trna synthetases
CA2858613A1 (en) 2011-12-29 2013-08-08 Atyr Pharma, Inc. Aspartyl-trna synthetase-fc conjugates
AU2013246418B2 (en) 2012-04-13 2017-02-23 Becton, Dickinson And Company Reflex testing of samples using residual materials from a prior test
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
US10913736B2 (en) 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
JP2019196307A (ja) * 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環アミド化合物
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
WO2019140265A1 (en) * 2018-01-12 2019-07-18 President And Fellows Of Harvard College Trna synthetase inhibitors
IL300723A (en) * 2020-08-25 2023-04-01 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd A method for extracting mupirocin

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1196284A (en) * 1982-05-28 1985-11-05 Joshua Oduro-Yeboah Pharmaceutical formulations
GB8415579D0 (en) * 1984-06-19 1984-07-25 Beecham Group Plc Compounds
IE59628B1 (en) * 1986-06-26 1994-03-09 Beecham Group Plc Treatment of fungal infections
DK0727979T3 (da) * 1993-10-22 2001-10-01 Smithkline Beecham Corp Nyt præparat
GB9424562D0 (en) * 1994-12-06 1995-01-25 Giltech Ltd Product
GB9507825D0 (en) * 1995-04-18 1995-05-31 Wet Pieter M De Method of treatment
US5726195A (en) * 1995-07-28 1998-03-10 Cubist Pharmaceuticals, Inc. Aminoacyl adenylate mimics as novel antimicrobial and antiparasitic agents
US6169102B1 (en) * 1996-06-25 2001-01-02 Takeda Chemical Industries, Ltd. Oxazolone derivatives and their use as anti-Helicobacter pylori agent
US6448059B1 (en) * 1996-09-13 2002-09-10 Thomas Jefferson University Methods and composition for inhibition of tRNA activities
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US5939458A (en) * 1997-09-22 1999-08-17 Henry; James P. Reduction of hair growth
CA2330564A1 (en) * 1998-04-29 1999-11-04 John Stephen Elder Quinolones used as mrs inhibitors and bactericides
WO2000017206A1 (en) * 1998-09-18 2000-03-30 Cubist Pharmaceuticals, Inc. Tetracyclic heterocycles as antimicrobial agents
GB9822241D0 (en) * 1998-10-12 1998-12-09 Smithkline Beecham Plc Novel compounds
CA2372079A1 (en) * 1999-05-05 2000-11-09 Aaron H. Leeman Novel catechols as antimicrobial agents
EP1176959B1 (en) * 1999-05-05 2006-03-08 Merck & Co., Inc. Novel prolines as antimicrobial agents
JP2003500397A (ja) * 1999-05-19 2003-01-07 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｍｒｓ阻害剤としての２−ｎｈ−ピリドンおよびピリミドン
GB9911594D0 (en) * 1999-05-19 1999-07-21 Smithkline Beecham Plc Novel compounds
IL137363A (en) * 2000-07-18 2005-12-18 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
GB0228545D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compounds
GB0302546D0 (en) * 2003-02-04 2003-03-12 Glaxo Group Ltd Novel compounds
WO2004078119A2 (en) * 2003-03-03 2004-09-16 Replidyne Inc. Substituted thiophenes with antibacterial activity
DE10318991A1 (de) * 2003-04-25 2004-11-18 Heraeus Kulzer Gmbh & Co. Kg Poröser Körper mit antibiotischer Beschichtung, Verfahren zur Herstellung sowie Verwendung

Also Published As

Publication number Publication date
JP2007502861A (ja) 2007-02-15
US20040224981A1 (en) 2004-11-11
WO2005009336A9 (en) 2005-04-14
WO2005009336A2 (en) 2005-02-03
EP1619947A2 (en) 2006-02-01
WO2005009336A3 (en) 2005-10-13
CA2523651A1 (en) 2005-02-03
EP1619947A4 (en) 2006-05-31

Similar Documents

Publication Publication Date Title
AU2004258821A1 (en) Antibacterial methods and compositions
RU2609259C2 (ru) Пиримидиновые ингибиторы гиразы и топоизомеразы iv
UA124661C2 (uk) Композиція, що містить антибіотик та диспергатор або антиадгезивний агент
CN103781787A (zh) 含氮化合物及其用途
US12150937B2 (en) NLRP3 modulators
KR20080038380A (ko) 항균제로서의 퀴놀린 유도체
RU2527769C2 (ru) Производные 5-гидроксиметилоксазолидин-2-она для лечения бактериальных кишечных заболеваний
US12187706B2 (en) NLRP3 modulators
KR20150089086A (ko) 박테리아 감염을 치료하기 위한 조성물 및 방법
JP6411482B2 (ja) 窒素含有化合物およびその使用
US9814719B2 (en) Methods and compositions for treating bacterial infection
AU2019349438B2 (en) Indane derivatives for use in the treatment of bacterial infection
US12016874B2 (en) Methods and compositions for treating carbapenem-resistant klebsiella pneumoniae infections
KR101850265B1 (ko) 항균제 및 타조박탐을 포함하는 조성물
EP1618106B1 (en) Carbacephem beta-lactam antibiotics
KR101329587B1 (ko) 항균제로서의 퀴놀린 유도체
US20180042928A1 (en) Methods and compositions for treating bacterial infection
AU2003303953B2 (en) Antibacterial pyrazole carboxylic acid hydrazides
US20210094954A1 (en) Preparation methods and applications of 3,5-disubstituted methylpyrazolo[1,5-a]pyrimidine-7-hydroxylic salts
KR20080021156A (ko) 항균제로서 퀴놀린 유도체
CN120665042A (zh) 活性氧激活型抗菌前药及其在治疗细菌感染中的应用
US20250161266A1 (en) Antibacterial 4.5 Diaryl-Thiophen-2-YL Hexafluoropropan-2-OLS
CN120424016A (zh) 一种多卤代喹唑啉酮生物碱及其在抗金黄色葡萄球菌中的应用
KR101318181B1 (ko) 항균제로서의 퀴놀린 유도체
CA3158337A1 (en) Nitrogen containing bicyclic compounds

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application